Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECT: FOLFOX vs. Chemoradiation in Rectal Cancer
NCT01515787Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2012
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of FOLFOX in rectal cancer, sponsored by Cancer and Leukemia Group B. Started Jun 2012; status: active, not recruiting.
02
Drugs
FOLFOX
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01515787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515787.